SLC7A5

Across TCGA pan-cancer cohorts, SLC7A5 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SLC7A5’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where SLC7A5 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC7A5 is over-expressed in tumor.

LSCC, COAD, and LUAD are the cancer types where SLC7A5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC7A5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	+1.794	<.001	9	view →
COAD	Male	II,III,IV	+1.350	<.001	9	view →
LUAD	Male	III,IV	+1.218	<.001	9	view →
CCRCC	All	III,IV	+0.763	<.001	9	view →
HNSC	All	III,IV	+0.511	<.001	7	view →
PDAC	All	III,IV	+1.280	.026	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SLC7A5–LSCC

Open the LSCC breakdown →